Febrile NeutropeniaNCT07277387
Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia
An observational study of Febrile Neutropenia, run by Instituto de Investigación Biomédica de Salamanca at 3 sites in Spain.
Trial summary
Febrile neutropenia (FN) is a common oncologic emergency in patients with hematologic malignancies, associated with high morbidity and mortality. Early identification of patients at higher risk of complications such as sepsis or septic shock is critical to optimize antimicrobial management. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Febrile Neutropenia
- What is being tested?
- Plasma and DNA sample collection for proteomic and genomic analysis
- How many people
- 350 participants
- Where
- 3 sitesSpain
- Study dates
- 9 Jun 2026to Jan 2029
- How long will I take part?
- 30 Days
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Oncohematologic Patients With Febrile Neutropenia
Who may be able to join
- Adults (≥18 years).
- Written informed consent provided by patient or legal representative.
- Diagnosis of hematologic malignancy under induction chemotherapy, post-allogeneic hematopoietic stem cell transplantation, or CAR-T therapy.
- High-risk febrile neutropenia (ANC ≤ 100 cells/mm³, expected duration ≥ 7 days, or significant comorbidities).
- Fever defined as oral temperature ≥38.3 °C once or ≥38.0 °C for ≥1 hour.
- Hospitalized or requiring immediate admission at the time of FN diagnosis.
Show all 9Show fewer
- ´- Initial uncomplicated clinical presentation, with no previous infection or colonization by multidrug-resistant bacteria.
- Eligible for initial monotherapy with broad-spectrum empirical antibiotic.
- Availability for serial plasma sampling and clinical follow-up.
Who cannot join
- Age <18 years.
- Low-risk FN according to MASCC/CISNE criteria.
- Initial sample collected after antibiotic administration.
- Decline or inability to provide informed consent.
- Any condition preventing safe participation or reliable sample collection.
- Fever induced by noninfectious causes (considered as adjustment factor, not exclusion).
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Spain3 sites, 3 recruiting
- Not yet recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona
- Recruiting
Complejo Asistencial Universitario de Salamanca
Salamanca, Salamanca, 37007
Jesús Francisco Bermejo Martín, PhD, +34923 29 45 41, jfbermejo@usal.es
- Not yet recruiting
Hospital Universitario Virgen Macarena
Seville, Sevilla
About this study
Official title: A Multicenter Prospective Observational Study on the Plasma Proteomic Profiling of Human and Microbial Proteins for the Early Identification of Biomarker Combinations (Combitypes) Associated With Complications in Oncohematologic Patients With Febrile Neutropenia
Febrile neutropenia (FN) is a common oncologic emergency in patients with hematologic malignancies, associated with high morbidity and mortality. Early identification of patients at higher risk of complications such as sepsis or septic shock is critical to optimize antimicrobial management.
This study aims to characterize the human and microbial plasma proteome using high-resolution mass spectrometry to identify biomarker combinations ("combitypes") capable of predicting complications in oncohematologic patients with FN.
A cohort of 350 adult patients with high-risk FN and initially uncomplicated clinical presentation will be enrolled across three tertiary hospitals. Plasma samples will be collected at fever onset (before antibiotic initiation) and after 48 hours. Proteomic data will be integrated with clinical information using multivariate and machine learning models to develop a predictive model for complications.
Read the detailed description
This multicenter, prospective, observational study will evaluate whether combined proteomic profiles of host and microbial origin can predict complications in patients with hematologic malignancies presenting with high-risk febrile neutropenia (FN).
FN is defined as an oral temperature ≥38.3 °C once or ≥38.0 °C for ≥1 hour in patients with an absolute neutrophil count (ANC) <500 cells/mm³ or expected to decrease below that threshold within 48 hours. Despite empirical broad-spectrum antibiotics, up to 50% of these patients develop sepsis, and 10% progress to septic shock.
Current biomarkers such as C-reactive protein (CRP) or procalcitonin (PCT) have limited specificity in this immunocompromised population. This study proposes a novel integrative proteomic approach based on mass spectrometry to simultaneously quantify host and microbial proteins in plasma, identifying molecular patterns associated with poor outcomes.
Plasma samples (10 mL, EDTA) will be obtained at two time points: the first febrile episode (prior to antibiotic administration) and 48 hours later. Proteins will be processed using PreOmics® ENRICHplus technology and analyzed via LC-MS/MS on an Evosep One-timsTOF Pro2 platform. Differentially expressed proteins will be identified using a data-independent acquisition (DIA-PASEF) workflow and validated in a subset of 200 patients through targeted mass spectrometry.
Clinical, analytical, and microbiological data will be collected via the REDCap platform. Machine learning models (XGBoost, SHAP interpretability) will be used to generate a predictive risk model for complications, integrating proteomic and clinical data.
This study is expected to establish a new decision-support tool for early identification of high-risk FN patients, facilitating personalized antimicrobial strategies and improved prognosis.
- Conditions
- Febrile Neutropenia
- Being tested
- Plasma and DNA sample collection for proteomic and genomic analysis
- Keywords
- febrile neutropenia, hematologic malignancy, proteomics, sepsis, biomarkers, septic shock, mass spectrometry
- Medical subject headings
- Febrile Neutropenia, Hematologic Neoplasms, Sepsis, Shock, Septic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Plasma and DNA sample collection for proteomic and genomic analysisBiological
Collection of 10 mL of peripheral blood in EDTA tubes at fever onset (before antibiotic initiation) and 48 hours later for proteomic and genomic analysis. Samples are processed to obtain plasma and DNA, which will be used for mass spectrometry-based proteomics and potential metagenomic studies.
| Study group | Role | What they receive |
|---|---|---|
| High-risk FN cohort | Adult onco-hematologic inpatients meeting inclusion criteria; two plasma draws at fever onset and 48 h. Receives: Biological: Plasma and DNA sample collection for proteomic and genomic analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identification of plasma host-microbial proteomic signatures (combitypes) associated with major complications in febrile neutropenia.
Evaluation of proteomic profiles (human and microbial) associated with hemodynamic instability, sepsis, septic shock, or death.
Measured: Within 7 days from fever onset.
Secondary outcomes (5)
Dynamic changes in plasma proteome over 48 hours
Assessment of longitudinal variations in host and microbial protein levels between baseline and 48 hours.
Measured: 0-48 hours
Predictive performance of identified combitypes versus conventional biomarkers (CRP, PCT)
Comparison of ROC-AUC for new proteomic models against current inflammatory markers.
Measured: Up to 7 days.
Correlation between microbial proteomic profiles and microbiologically documented infections
Association between detected microbial peptides and confirmed pathogens.
Measured: During hospitalization (up to 30 days).
Development of a predictive model for complications
A predictive risk model for complications will be developed using machine-learning algorithms (XGBoost) based on the integration of plasma proteomic data and relevant clinical parameters collected at fever onset and during follow-up. The model will be trained and internally validated within the full study cohort using cross-validation techniques to optimize predictive performance and minimize overfitting.
Measured: Study duration (36 months).
Validation of selected protein biomarkers by targeted mass spectrometry
Selected protein biomarkers previously identified through discovery-phase proteomic profiling will be validated using targeted LC-MS/MS mass spectrometry in plasma samples from 200 patients within the study cohort. This validation phase will assess the analytical performance (including reproducibility, accuracy, and sensitivity) of the selected biomarkers, as well as their clinical relevance in predicting complications such as hemodynamic instability, sepsis, septic shock, or death. This outcome cannot be divided into sepparate ones, as biomarker expression will be analyzed as a whole, given the fact that until the trial begins, the biomarkers associated with complications in oncohematologic patients with febrile neutropenia will be unkown. This outcome will determine the feasibility of implementing the identified biomarkers as prognostic tools in routine clinical practice for the early risk stratification of patients
Measured: By end of study (month 36).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2025
- Study start9 Jun 2026
- Primary completionDec 2028 (estimated)
- Study completionJan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Febrile NeutropeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 350 participants (estimated)
- Target duration
- 30 Days
Sponsor and investigators
- Lead sponsor
- Instituto de Investigación Biomédica de Salamanca
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jesús Francisco Bermejo Martín, MD PhD, Principal investigator, Centro Asistencial Universitario de Salamanca (CAUSA)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07277387
- Sponsor's protocol ID
- COMBITYPES-FN
- Status last verified
- Apr 2026
- First submitted
- 18 Nov 2025
- Last updated
- 15 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Following anonymization, individual participant-level data supporting the publications will be made available. These data include demographic and clinical variables collected in REDCap. A data dictionary, eCRF, and-when possible-analysis scripts (R/Python) and FAIR-compliant metadata will also be provided. Data will be hosted within the controlled infrastructure of the project (XNAT/Core-lab) and, for controlled dissemination, within the Zenodo community of IBSAL, with DOI assignment and regulated access, in accordance with the GDPR/LOPDGDD and the study protocol as approved by the Research Ethics Committee.
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Prospective Observational Study on the Plasma Proteomic Profiling of Human and Microbial Proteins for the Early Identification of Biomarker Combinations (Combitypes) Associated With Complications in Oncohematologic Patients With Febrile Neutropenia
- ClinicalTrials.gov ID
- NCT07277387
- Acronym / sponsor ID
- COMBITYPES-FN
- Conditions
- Febrile Neutropenia
- Keywords
- febrile neutropenia, hematologic malignancy, proteomics, sepsis, biomarkers, septic shock, mass spectrometry
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 350 participants (estimated)
- Lead sponsor
- Instituto de Investigación Biomédica de SalamancaUniversity, hospital or other
- Study start
- 9 Jun 2026 (actual)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Jan 2029 (estimated)
- First posted
- 11 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Febrile neutropenia (FN) is a common oncologic emergency in patients with hematologic malignancies, associated with high morbidity and mortality. Early identification of patients at higher risk of complications such as sepsis or septic shock is critical to optimize antimicrobial management.
This study aims to characterize the human and microbial plasma proteome using high-resolution mass spectrometry to identify biomarker combinations ("combitypes") capable of predicting complications in oncohematologic patients with FN.
A cohort of 350 adult patients with high-risk FN and initially uncomplicated clinical presentation will be enrolled across three tertiary hospitals. Plasma samples will be collected at fever onset (before antibiotic initiation) and after 48 hours. Proteomic data will be integrated with clinical information using multivariate and machine learning models to develop a predictive model for complications.
Detailed description
This multicenter, prospective, observational study will evaluate whether combined proteomic profiles of host and microbial origin can predict complications in patients with hematologic malignancies presenting with high-risk febrile neutropenia (FN).
FN is defined as an oral temperature ≥38.3 °C once or ≥38.0 °C for ≥1 hour in patients with an absolute neutrophil count (ANC) <500 cells/mm³ or expected to decrease below that threshold within 48 hours. Despite empirical broad-spectrum antibiotics, up to 50% of these patients develop sepsis, and 10% progress to septic shock.
Current biomarkers such as C-reactive protein (CRP) or procalcitonin (PCT) have limited specificity in this immunocompromised population. This study proposes a novel integrative proteomic approach based on mass spectrometry to simultaneously quantify host and microbial proteins in plasma, identifying molecular patterns associated with poor outcomes.
Plasma samples (10 mL, EDTA) will be obtained at two time points: the first febrile episode (prior to antibiotic administration) and 48 hours later. Proteins will be processed using PreOmics® ENRICHplus technology and analyzed via LC-MS/MS on an Evosep One-timsTOF Pro2 platform. Differentially expressed proteins will be identified using a data-independent acquisition (DIA-PASEF) workflow and validated in a subset of 200 patients through targeted mass spectrometry.
Clinical, analytical, and microbiological data will be collected via the REDCap platform. Machine learning models (XGBoost, SHAP interpretability) will be used to generate a predictive risk model for complications, integrating proteomic and clinical data.
This study is expected to establish a new decision-support tool for early identification of high-risk FN patients, facilitating personalized antimicrobial strategies and improved prognosis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 30 Days
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| High-risk FN cohort | – | Biological: Plasma and DNA sample collection for proteomic and genomic analysisAdult onco-hematologic inpatients meeting inclusion criteria; two plasma draws at fever onset and 48 h. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Oncohematologic Patients With Febrile Neutropenia
Key inclusion criteria (9 listed)
- Adults (≥18 years).
- Written informed consent provided by patient or legal representative.
- Diagnosis of hematologic malignancy under induction chemotherapy, post-allogeneic hematopoietic stem cell transplantation, or CAR-T therapy.
- High-risk febrile neutropenia (ANC ≤ 100 cells/mm³, expected duration ≥ 7 days, or significant comorbidities).
- Fever defined as oral temperature ≥38.3 °C once or ≥38.0 °C for ≥1 hour.
Key exclusion criteria (6 listed)
- Age <18 years.
- Low-risk FN according to MASCC/CISNE criteria.
- Initial sample collected after antibiotic administration.
- Decline or inability to provide informed consent.
- Any condition preventing safe participation or reliable sample collection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Plasma and DNA sample collection for proteomic and genomic analysisCollection of 10 mL of peripheral blood in EDTA tubes at fever onset (before antibiotic initiation) and 48 hours later for proteomic and genomic analysis. Samples are processed to obtain plasma and DNA, which will be used for mass spectrometry-based proteomics and potential metagenomic studies. | Biological | High-risk FN cohort |
Primary outcome
Identification of plasma host-microbial proteomic signatures (combitypes) associated with major complications in febrile neutropenia.
Time frame: Within 7 days from fever onset.
Evaluation of proteomic profiles (human and microbial) associated with hemodynamic instability, sepsis, septic shock, or death.
5 secondary outcomes
Dynamic changes in plasma proteome over 48 hours
Time frame: 0-48 hours
Predictive performance of identified combitypes versus conventional biomarkers (CRP, PCT)
Time frame: Up to 7 days.
Correlation between microbial proteomic profiles and microbiologically documented infections
Time frame: During hospitalization (up to 30 days).
Development of a predictive model for complications
Time frame: Study duration (36 months).
Validation of selected protein biomarkers by targeted mass spectrometry
Time frame: By end of study (month 36).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2026.
- Individual participant dataSharing planned: Yes. Following anonymization, individual participant-level data supporting the publications will be made available. These data include demographic and clinical variables collected in REDCap. A data dictionary, eCRF, and-when possible-analysis scripts (R/Python) and FAIR-compliant metadata will also be provided. Data will be hosted within the controlled infrastructure of the project (XNAT/Core-lab) and, for controlled dissemination, within the Zenodo community of IBSAL, with DOI assignment and regulated access, in accordance with the GDPR/LOPDGDD and the study protocol as approved by the Research Ethics Committee.
Related trials for Febrile Neutropenia
RecruitingPhase 4
Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance
Febrile Neutropenia
Not yet recruiting
Diagnostic Accuracy, Clinical Utility and Implementation of Point-of-Care Absolute Neutrophil Count in Suspected Neutropenic Fever (DUCATIS) - Diagnostic Accuracy (S1)
Suspected Neutropenic Fever, Confirmed Neutropenic Fever
RecruitingObservational study
Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
Breast Cancer, Chemotherapy-induced Neutropenia
Not yet recruiting
Impact of a Telemonitoring Device on the Occurever at Home in Children at Risk of Chemotherapy-Induced Neutropenia
Oncopediatrics, Febrile Neutropenia
Recruiting
Swiss 2024 Continous Fever Monitoring in Pediatric Oncology Patients
Pediatric Oncology Patients With Risk for Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jesús Francisco Bermejo Martín, MD PhD principal investigator
Centro Asistencial Universitario de Salamanca (CAUSA)
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Febrile Neutropenia, run by Instituto de Investigación Biomédica de Salamanca at 3 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jesús Francisco Bermejo Martín, MD PhD (+34923 29 45 41, jfbermejo@usal.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identification of plasma host-microbial proteomic signatures (combitypes) associated with major complications in febrile neutropenia. (time frame: Within 7 days from fever onset.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.